Profile of adult patients admitted with drug-induced liver injury at a district hospital in Pietermaritzburg, KwaZulu-Natal

References

• Menezes C. An approach to the management of Drug-induced liver injury in HIV- infected patients treated for Tuberculosis. Department of Internal Medicine (Power Point Slides 1–43) [cited 2019 Jan 23]. Available from https://sahivsoc.org
   Google Scholar
• Wang S, Shangguan Y, Ding C, et al. Risk factors for acute liver failure among inpatients with anti-tuberculosis drug-induced liver injury. J Int Med Res. November 26, 2018. [cited 2019 Jan 23]. https://doi.org/10.1177/0300060518811512
   Google Scholar
• Wood R, Bekker LG. Isoniazid preventive therapy for tuberculosis in South Africa: An assessment of the local evidence base. SAMJ. 2014;104(3):174–177 [ cited 2017 Jan 13]. doi: 10.7196/SAMJ.7968
   PubMed Web of Science ®Google Scholar
• Department of Health. KZN Department of Health Implements HIV ‘Test and Treat’ Policy Media Relase: 01 September 2016 [cited 2016 Dec 12]. Available from www.kznhealth.gov.za
   Google Scholar
• The Global Tuberculosis report. 2016 [cited 2017 Mar 18]. Available from: www.who.int/tb/data
   Google Scholar
• Jong E, Conradie F, Berhanu R, et al. Consensus statement: Management of drug-induced liver injury in HIV-positive patients treated for TB. South Afr J HIV Med. 2013;14(3):113–119. doi: 10.4102/sajhivmed.v14i3.63
   Google Scholar
• Cohen K, Meintjes G. Management of individuals requiring ART and TB treatment. Curr Opin HIV AIDS. 2010 Jan;5(1):61–69 [cited 2017 Apr 21]. Available from: www.ncbi.nlm.nih.gov doi: 10.1097/COH.0b013e3283339309
   PubMed Web of Science ®Google Scholar
• Schutz C, Ismail Z, Proxenos CJ, et al. Burden of antituberculosis and antiretroviral drug-induced liver injury at a secondary hospital in South Africa. S Afr Med J. 2012;102(6):506–511. doi: 10.7196/SAMJ.5650
   PubMed Web of Science ®Google Scholar
• Department of health. District health plan 2015–2016 [cited 2016 Dec 20]. Available from www.kznhealth.gov.za
   Google Scholar
• Global HIV and AIDA statistics- 2018 fact sheet. UNAIDS Report on the AIDS epidemic Geneva UNAIDS, 2016, 2016 [cited 2019 Jan 22]. Available from www.unaids.org
   Google Scholar
• Drug Induced Liver Injury. Up-to-date: [cited 2019 Aug 8]. Available from http://www.uaeps.me
   Google Scholar
• Fontana RJ, Watkins PB, Bonkovsky HL, et al. Drug induced liver injury network (DILIN)- prospective study. Drug Sa. 2009;32(1):55–68. doi: 10.2165/00002018-200932010-00005
   PubMed Web of Science ®Google Scholar
• McGovern BH, Sulkowski MS, Sterling RK. Chapter 38 – HIV Co-infection drug toxicity. In: Sanyal TDBPMJ, editor. Zakim and Boyer's hepatology. 6th ed. Saint Louis: W.B. Saunders; 2012. p. 683–699.
   Google Scholar
• Devarbhavi H. An update on drug-induced liver injury. J Clin Exp Hepatol. 2012 9;2(3):247–259. doi: 10.1016/j.jceh.2012.05.002
   PubMedGoogle Scholar
• Vuppalanchi R, Chalasani N. Chapter 16 – Risk factors for drug-induced liver disease. In: DeLeve NKD, editor. Drug-induced liver disease. 3rd ed. Boston: Academic Press; 2013. p. 265–274.
   Google Scholar
• Fontana RJ, Hayashi PH, Gu J, et al. Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 Months from onset. Gastroenterology. 2014;147(1):96–108.e4. doi: 10.1053/j.gastro.2014.03.045
   PubMed Web of Science ®Google Scholar
• Torres DM, Stevens RD, Gurakar A. Acute liver failure, a management challenge for the practicing Gastroenterlogist. Gastroenterol Hepatol (NY). 2010 Jul;6(7):444–450.
   PubMedGoogle Scholar
• Wong WM, Wu PC, Yuen MF, et al. Antituberculosis drug- related liver dysfunction in chronic hepatitis B. Hepatology. 2000;31:201–206. doi: 10.1002/hep.510310129
   PubMed Web of Science ®Google Scholar
• Huang Y-S. Recent progress in genetic variation and risk of antituberculosis drug-induced liver injury. J Chin Med Assoc. 2014;77(4):169–173. doi: 10.1016/j.jcma.2014.01.010
   PubMed Web of Science ®Google Scholar
• Singla N, Gupta D, Birbian N, et al. Association of NAT2. GST and CY: 2E, 1 polymorphisms and anti-tuberculosis drug-induced hepatotoxicity. Tuberculosis. 2014;94(3):293 –298. doi: 10.1016/j.tube.2014.02.003
   PubMed Web of Science ®Google Scholar
• Mitchell JR, Zimmerman HJ, Ishak KG, et al. Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis. Ann Intern Med. 1976 Feb;84(2):181–192. doi: 10.7326/0003-4819-84-2-181
   PubMed Web of Science ®Google Scholar
• Chalasani N, Fontana RJ, Bonkovsky HL, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology. 2008 Dec;135(6):1924–1934. 34 e1–4. PubMed PMID: 18955056. Pubmed Central PMCID: PMC3654244. Epub 2008/10/29. eng. doi: 10.1053/j.gastro.2008.09.011
   PubMed Web of Science ®Google Scholar
• Regev A, Björnsson ES. Drug-induced liver injury: morbidity, mortality, and Hy’s law. Gastroenterology. 2014;147(1):20–24. doi: 10.1053/j.gastro.2014.05.027
   PubMed Web of Science ®Google Scholar